相关实验视频
Updated: Sep 13, 2025

11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
8.0K
爱尔兰前列腺癌的焦点治疗:解决国家客观和主观需求
Robert A Keenan1, Kevin Keane2, Jody Khan2
1Department of Urology, St. James's Hospital, James's Street, Dublin 8, Ireland. robertanthonykeenan@rcsi.ie.
Irish journal of medical science
|July 27, 2025
概括
在爱尔兰,多达一半的局部性前列腺癌患者可能适合焦点治疗,这是一个尚未广泛使用的治疗方法. 专家们对引入这种先进的前列腺癌治疗有很大的兴趣.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗技术 医疗技术 医学技术
背景情况:
- 焦点治疗是一种经过NICE和EAU批准的局部性前列腺癌治疗方法.
- 它还没有在爱尔兰,需要评估其潜在的实施.
- 这项研究评估了爱尔兰患者适应性和专家对焦点治疗的态度.
研究的目的:
- 确定爱尔兰适合焦点治疗的前列腺癌患者的比例.
- 评估爱尔兰泌尿科医生关于焦点治疗的当前知识和态度.
- 为了确定在爱尔兰引入焦点治疗服务的障碍和促进者.
主要方法:
- 对新诊断前列腺癌患者的放射学和临床病理学参数的回顾性审查.
- 根据定义的标准,对患者适用于焦点治疗的专家评估.
- 全国调查咨询泌尿科医生和实习生关于他们对焦点治疗的知识和态度.
主要成果:
- 在191名局部疾病患者中,50%在技术上适合,27%是焦点治疗的理想候选人.
- 调查响应率为48%,其中94%的受访者经常管理前列腺癌诊断.
- 近90%的受访者目前并没有向患者介绍焦点治疗作为一种选择,但44%的实习生和50%的顾问对学习焦点治疗感兴趣.
结论:
- 很大一部分爱尔兰前列腺癌患者适合集中治疗.
- 爱尔兰泌尿科医生对采用焦点治疗有很大的兴趣,尽管目前缺乏暴露.
- 在爱尔兰开发焦点治疗服务有可能使大量患者受益.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

